Aortic valvular calcification predicts restenosis after implantation of drug-eluting stents in patients on chronic haemodialysis.

BACKGROUND Even in the drug-eluting stent (DES) era, the restenosis rate of the follow-up period after percutaneous coronary intervention (PCI) is higher in haemodialysis (HD) patients than in non-HD patients. Therefore, higher restenosis remains a clinical limitation in HD patients, and a simple clinical method to predict patients likely to have restenosis after stent implantation is attractive. The present study investigated the potential relationship between aortic valvular calcification (AVC) and angiographical restenosis at follow-up after DES implantation in patients on maintenance HD. METHODS In the study, 97 patients were enrolled. We prospectively performed echocardiography before elective PCI with DES implantation. Angiographic follow-up was scheduled between 6 and 8 months after PCI. Restenosis at follow-up was defined as a diameter stenosis of > or =50% by measuring quantitative coronary angiography. RESULTS Of the enrolled patients, 59 patients (60.8%) had AVC. Complete angiographical follow-up was obtained in 86 patients (88.7%). The angiographical restenosis rate during the follow-up period was 24.7% in patients with AVC and 8.9% in patients without AVC [hazard ratio (HR) 3.36; 95% confidence interval (CI) 1.18-9.56, P = 0.023]. Even after multivariate adjustment including covariates related to atherogenecity, AVC remained an independent predictor of restenosis after implanting DES (HR 3.83; 95% CI 1.14-12.9, P = 0.029). Late lumen loss suggesting neointimal growth after DES implantation was 0.28 +/- 0.70 mm in the non-AVC group and 0.64 +/- 0.90 mm in the AVC group (P = 0.013). CONCLUSIONS AVC provides predictive information regarding DES implantation in patients on maintenance HD.

[1]  G. Helft,et al.  Clinical outcome following coronary angioplasty in dialysis patients: a case–control study in the era of coronary stenting , 2001, Heart.

[2]  G. Nakazawa,et al.  Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus‐eluting stents , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[3]  A. Collins,et al.  Comparative Survival of Dialysis Patients in the United States After Coronary Angioplasty, Coronary Artery Stenting, and Coronary Artery Bypass Surgery and Impact of Diabetes , 2002, Circulation.

[4]  G. Eknoyan,et al.  Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2006, Kidney international.

[5]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[6]  M. Nakamura,et al.  Independent predictors of restenosis after percutaneous coronary revascularization in haemodialysis patients. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  E. Milford,et al.  The relationship between serum calcium and phosphate levels and cardiac valvular procedures in the hemodialysis population. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  P. Serruys,et al.  Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. , 2005, The American journal of cardiology.

[9]  R. Virmani,et al.  Coronary angioplasty from the perspective of atherosclerotic plaque: morphologic predictors of immediate success and restenosis. , 1994, American heart journal.

[10]  K. Kent,et al.  Impact of chronic renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary intervention with sirolimus-eluting stents versus bare metal stents. , 2006, The American journal of cardiology.

[11]  J. Loscalzo,et al.  Vascular Calcification: Pathobiological Mechanisms and Clinical Implications , 2006, Circulation research.

[12]  O. Alfieri,et al.  Percutaneous Treatment With Drug-Eluting Stent Implantation Versus Bypass Surgery for Unprotected Left Main Stenosis: A Single-Center Experience , 2006, Circulation.

[13]  P. Fitzgerald,et al.  Contribution of Localized Calcium Deposits to Dissection After Angioplasty: An Observational Study Using Intravascular Ultrasound , 1992, Circulation.

[14]  J. Zamorano,et al.  Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. , 2007, Journal of the American College of Cardiology.

[15]  Thomas J. Ryan,et al.  Guidelines for Percutaneous Transluminal Coronary Angioplasty A Report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty) , 1993, Circulation.

[16]  K. Shimada,et al.  Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study , 2004, Circulation.

[17]  J. Woo,et al.  Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. , 2003, Journal of the American Society of Nephrology : JASN.

[18]  J. Popma,et al.  The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). , 2004, Journal of the American College of Cardiology.

[19]  F. Fernández‐Avilés,et al.  Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial , 2005, Circulation.

[20]  J. Floege,et al.  Calcification and Cardiovascular Health: New Insights Into an Old Phenomenon , 2006, Hypertension.

[21]  M. Rocco,et al.  Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. , 2000, Kidney international.

[22]  J. Couet,et al.  Experimental aortic valve stenosis in rabbits. , 2003, Journal of the American College of Cardiology.

[23]  I. Iakovou,et al.  Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions , 2005 .

[24]  M. Yoshiyama,et al.  2 An Attempt of Increasing the Quality and Quantity of Cardiac Rehabilitation Program(Symposium 16 (SY-16) (H) Cardiac Rehabilitation : Innovative Approach to Improve Patient Care,Special Program,The 72nd Annual Scientific Meeting of the Japanese Circulation Society) , 2008 .

[25]  D. Holmes,et al.  Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failure. , 2001, American Journal of Cardiology.

[26]  R. Foley,et al.  Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease and cardiac failure. Semin Dial 2003 , 2022 .

[27]  E. Ritz,et al.  Calcification and cardiovascular problems in renal failure. , 2005, Kidney international. Supplement.

[28]  T. Ryan.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Journal of the American College of Cardiology.

[29]  G. London,et al.  Pathophysiology of cardiovascular disease in hemodialysis patients. , 2000, Kidney international. Supplement.

[30]  R. Brant,et al.  Poor long-term survival after coronary angiography in patients with renal insufficiency. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  S. Stock,et al.  Atorvastatin Inhibits Hypercholesterolemia-Induced Calcification in the Aortic Valves via the Lrp5 Receptor Pathway , 2005, Circulation.

[32]  F. Loop,et al.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Circulation.

[33]  P. Li,et al.  Cardiac valvular calcification as a marker of atherosclerosis and arterial calcification in end-stage renal disease. , 2005, Archives of internal medicine.

[34]  C. Zoccali,et al.  Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  Knud Erik Pedersen,et al.  Regression of Coronary Atherosclerosis by Simvastatin: A Serial Intravascular Ultrasound Study , 2004, Circulation.

[36]  Masato Nakamura,et al.  Favourable long-term outcome by repeated percutaneous coronary revascularization in diabetic haemodialysis patients. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  W. Qunibi.  Reducing the burden of cardiovascular calcification in patients with chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[38]  Hiroshi Takahashi,et al.  Sirolimus-eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[39]  Hiroshi Takahashi,et al.  Comparison of percutaneous coronary intervention with medication in the treatment of coronary artery disease in hemodialysis patients. , 2006, Journal of the American Society of Nephrology : JASN.